Kineta Press Release Archives
-
Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit
June 17, 2022 by Kineta Inc
-
Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022
May 18, 2022 by Kineta Inc
-
Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022
April 13, 2022 by Kineta Inc
-
Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022
March 21, 2022 by Kineta Inc
-
Kineta Invited to Participate in the Cowen 42nd Annual Health Care Virtual Conference
February 24, 2022 by Kineta Inc
-
Kineta to Present on the Company’s PiiONEER™ Platform at the 6th Annual Tumor Models for Immuno-oncology Summit
January 24, 2022 by Kineta Inc
-
Kineta to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 11, 2022 by Kineta Inc
-
Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021
December 17, 2021 by Kineta Inc
-
Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 29, 2021 by Kineta Inc
-
Kineta Presented Compelling Preclinical Data on its New CD27 Antibody Program at the 2021 SITC Annual Meeting
November 16, 2021 by Kineta Inc
-
Kineta Presents Preclinical Data on its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy
October 7, 2021 by Kineta Inc
-
Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
September 28, 2021 by Kineta Inc
-
Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference
September 25, 2021 by Kineta Inc
-
Kineta Announces Patent Issuance of U.S. Patent for Composition of Matter of KCP506
August 10, 2021 by Kineta Inc
-
Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1
July 27, 2021 by Kineta Inc
-
Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody
July 20, 2021 by Kineta Inc
-
Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506
July 14, 2021 by Kineta Inc
-
Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA
June 24, 2021 by Kineta Inc
-
Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual Symposium
June 7, 2021 by Kineta Inc
-
Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021
April 12, 2021 by Kineta Inc
-
Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)
March 25, 2021 by Kineta Inc
-
Kineta Presenting at Multiple Investor Conferences in March 2021
March 3, 2021 by Kineta Inc
-
Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain
December 15, 2020 by Kineta Inc
-
Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies
December 9, 2020 by Kineta Inc
-
Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies
November 12, 2020 by Kineta Inc
-
Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Special Conference on Tumor Immunology and Immunotherapy
October 20, 2020 by Kineta Inc
-
Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid
October 8, 2020 by Kineta Inc
-
Kineta to Participate in BIO Investor Forum Digital
October 2, 2020 by Kineta Inc
-
Kineta to Present at September 2020 Virtual Investor Conferences
September 11, 2020 by Kineta Inc
-
Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506
August 12, 2020 by Kineta Inc
-
Kineta Invited to Present at August 2020 Investor Conferences
July 30, 2020 by Kineta Inc
-
Kineta to Present at July 2020 Virtual Investor Events
July 3, 2020 by Kineta Inc
-
Kineta Closes Investment Round to Advance Early Preclinical Development of Immuno-oncology Programs
May 5, 2020 by Kineta Inc
-
Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory Board
April 21, 2020 by Kineta Inc
-
Kineta to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference
March 25, 2020 by Kineta Inc
-
Kineta Invited to Participate at the Opal Group’s Family Office Winter Forum in New York
February 28, 2020 by Kineta Inc
-
Kineta Invited to Participate at the Cowen and Company 40th Annual Health Care Conference
February 27, 2020 by Kineta Inc
-
Kineta Invited to Participate at the BIO CEO & Investor Conference
February 5, 2020 by Kineta Inc
-
Kineta Invited to Participate at the 2nd Annual Evercore ISI HealthCONx Conference
November 26, 2019 by Kineta Inc
-
Kineta Invited to Participate at October 2019 Investor Conferences
October 7, 2019 by Kineta Inc
-
Kineta Invited to Participate at the H.C. Wainwright 21st Annual Global Investment Conference
August 29, 2019 by Kineta Inc
-
Kineta Invited to Participate at Solebury Trout’s 9th Annual CEO Roundtable Conference
August 12, 2019 by Kineta Inc
-
Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535
August 6, 2019 by Kineta Inc
-
Kineta Secures NIAID Grant Worth Up to $5.8M to Evaluate LHF-535 in Arenaviruses
July 15, 2019 by Kineta Inc
-
Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences Conference
May 28, 2019 by Kineta Inc
-
Kineta Invited to Present at the 2019 Life Science Innovation Northwest Conference
March 29, 2019 by Kineta Inc
-
Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies
December 17, 2018 by Kineta Inc
-
Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa Fever
September 5, 2018 by Kineta Inc
-
Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech
April 16, 2018 by Kineta Inc
-
Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models
April 5, 2018 by Kineta Inc
-
Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference
March 23, 2018 by Kineta Inc
-
Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference
January 22, 2018 by Kineta Inc
-
Kineta Appoints Michael Banks as New Chief Financial Officer
January 2, 2018 by Kineta Inc
-
Kineta to Present at Symposium on Pandemic Preparedness
June 12, 2017 by Kineta Inc
-
Kineta to Present at Symposium on Next-Generation Therapeutics for the Treatment of Pain
April 25, 2017 by Kineta Inc
-
Kineta to Present at the Planet MicroCap Showcase 2017
April 21, 2017 by Kineta Inc
-
Kineta to Present at the 24th Annual Future Leaders in the Biotech Industry Conference
April 4, 2017 by Kineta Inc
-
Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model
March 23, 2017 by Kineta Inc
-
KCP-400 Relieves Chronic Pain and Demonstrates Disease Modifying Effects
February 22, 2017 by Kineta Inc
-
Kineta to Present at Biotech Showcase Investor Conference during JP Morgan Week in San Francisco
January 6, 2017 by Kineta Inc
-
Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor Forum
October 31, 2016 by Kineta Inc
-
Kineta CEO Unveils its Immuno-oncology Program at the BIO Investor Forum
October 19, 2016 by Kineta Inc
-
UPDATE: Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals Against Zika Virus UPDATE
August 18, 2016 by Kineta Inc
-
Kineta Secures NIAID Funding to Expand Testing of Immune Modulators
July 31, 2016 by Kineta Inc
-
Kineta Presents Promising New Vaccine Adjuvant Data at American Association of Immunologists Annual Meeting
May 16, 2016 by Kineta Inc
-
Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials
May 5, 2016 by Kineta Inc
-
Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals
April 22, 2016 by Kineta Inc
-
Kineta Announces Promising New Data for KIN 1148 – a Novel Vaccine Adjuvant for Highly Pathogenic Flu
March 31, 2016 by Kineta Inc
-
Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress
March 22, 2016 by Kineta Inc